PitchSend

Investor Presentaiton

Consolidate MenQuadfi market leadership sanofi International roll-out ongoing MenQuadfi registered in 53 countries and expanding WHO pre-qualified > Best-in-Class MenACWY profile Novel serogroup-specific design, unique chemical and structural features - Higher serogroup C responses Fully-liquid presentation O Broad age-indication - Up to 7 years persistence in different age groups > Leadership in the U.S. with >60% MS source: Sanofi DDD CDC & others 70 Vaccines Investor Event

View entire presentation